ReviewClinical microbiology reviews2020
Review in Clinical microbiology reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 160 citations in OpenAlex.
- Microbiome and Pathobiome Characterization in Farmed Barramundi (Lates calcarifer) During and Post Scale Drop Disease Outbreaks.Journal of fish diseases · 2026Article
- Multicentre outbreak ofEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Burkholderia arboris bacteremia initially identified as Burkholderia cepacia complex: a genome-based case report.Archives of microbiology · 2026Article
- Design of solid phase microextraction patches for the detection of volatile metabolites associated with Burkholderia cepacia.Applied microbiology and biotechnology · 2026Article
- Genomic Insights into a New Burkholderia cenocepacia Sequence Type Linked to Cepacia Syndrome in Cystic Fibrosis.Current microbiology · 2026Article
- Hospital-Based Cross-Sectional Study ofGeoHealth · 2026Article
- Draft genome dataset ofData in brief · 2026Article
- Human infections caused by pathogenic Burkholderia: current clinical challenges and future perspectives.Infection · 2026Review
- Managing Pneumonia Due to Rare Non-Fermenting Gram-Negative Bacteria: Epidemiology, Risk Factors and Therapeutic Strategies.Antibiotics (Basel, Switzerland) · 2026Review
- Review
- Laboratory strategies for the identification of Burkholderia species: From classical phenotyping to advanced genomic and proteomic approaches.Antonie van Leeuwenhoek · 2026Review
- Transposon sequencing revealsApplied and environmental microbiology · 2026Article
- Adaptation of Burkholderia cenocepacia to low oxygen drives changes consistent with adaptation to chronic infection.BMC microbiology · 2026Article
- Article
- Microbial Landscape of Pharmaceutical Failures: A 21-Year Review of FDA Enforcement Reports.Biotech (Basel (Switzerland)) · 2026Review
- Antibodies toMicroorganisms · 2026Article
- The secretome of the environmental bacteriumMicrobiology spectrum · 2026Article
- Burkholderia cepacia complex bacteremia: an outbreak investigation with epidemiological link to contaminated disinfectant.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Pan-genome analysis identifies aFrontiers in microbiology · 2026Article
- Leveraging whole-genome sequencing for microbial contamination tracking and risk assessment in pharmaceutical manufacturing.Frontiers in microbiology · 2026Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.